Intraperitoneal Catumaxomab Therapy in a Cirrhotic Patient with Malignant Ascites due to Urethelial Carcinoma: A Case ReportKrawczyk M. · Zimmermann S. · Vidacek D. · Lammert F.
Department of Medicine II, Saarland University Medical Center, Homburg, Germany
Background: Refractory malignant ascites is a common complication in tumor patients. To date, chemotherapy and paracentesis represent the most widely used methods to relieve the symptoms. Lately, intraperitoneal therapy with catumaxomab, a trifunctional hybrid antibody, has been introduced for the treatment of malignant ascites, and its utility has been demonstrated in patients with distinct abdominal malignancies. Case Report: We report the first case of successful catumaxomab treatment of malignant ascites in a patient with advanced carcinoma of the urinary bladder and liver cirrhosis. Although at admission a largevolume paracentesis was needed every other day, paracentesis was no longer necessary after catumaxomab therapy. Conclusion: Catumaxomab might represent a safe treatment option for malignant ascites in the course of metastatic urothelial carcinoma, also in the setting of liver cirrhosis.
|Direct payment||This item at the regular price: USD 33.00|
|Payment from account||With a Karger Pay-per-View account (down payment USD 150)
you profit from a special rate for this and other single items.
This item at the discounted price: USD 23.00